Press release

New genetic discovery could improve diagnosis of childhood TB

A distinctive genetic 'signature' found in the blood of children with tuberculosis (TB) offers new hope for improved diagnosis of the disease.

TB is very difficult to diagnose in children. It is often recognised late when a child is already critically ill and the disease has spread from the lungs to the brain or other organs. However, an international team of researchers has shown that the disease can now be identified in over 80 per cent of cases by looking at 51 specific genes in the blood of affected children.

The researchers hope the findings - published on 30 April in the 'New England Journal of Medicine' - could be used to develop a cheap, quick and effective diagnostic test.

Lead researcher Professor Michael Levin, Director of the Wellcome Trust-funded Imperial College Centre for Global Health Research, explained: "We urgently need better methods to diagnose TB in children, so treatment can be started earlier and to avoid unnecessary treatment of children who are wrongly diagnosed. The symptoms of TB in children are common to many other childhood diseases, and the standard tests used on adults are not effective in children. Although the disease is treatable, thousands of children still die each year due to late diagnosis and many more are left with damage to their brain, bones and lungs."

The study - funded by the EU and carried out at Wellcome Trust-supported units in Africa - looked at over 2,800 children with symptoms of TB admitted to hospitals in South Africa, Malawi and Kenya. The researchers identified those proven to have TB and those in whom TB was excluded as the cause of their illness.

Blood samples from the South African and Malawian children were examined to see which genes were activated or suppressed in those with the disease. The researchers found that TB could be distinguished from other diseases by looking at just 51 genes from over 30,000 in the human genome and seeing whether they were activated or suppressed. This information was used to give a single TB risk score for each child, which, when tested in the Kenyan patients, accurately diagnosed over 80 per cent of those with TB. Conversely, a negative result accurately ruled out a diagnosis of TB.

Professor Levin said: "It has taken seven years and the combined efforts of clinicians and scientists in the UK, Africa and Singapore to identify this gene signature of childhood TB. What we now need is collaboration from biotechnology and industrial partners to turn these findings into a simple, rapid and affordable test for TB that can be used in hospitals worldwide."

According to World Health Organization statistics, across the world TB is second only to HIV/AIDS as the greatest cause of death due to a single infectious agent. Children represent a significant proportion of TB cases worldwide. An estimated 530,000 children became ill with TB in 2012 and 74,000 HIV-negative children died of TB.

Professor Brian Eley from the University of Cape Town, who led the clinical study in South Africa, said: "Childhood TB is a major problem in African hospitals. An accurate test for childhood TB would be an enormous breakthrough, enabling earlier diagnosis, reducing long hospital admissions for investigation of TB suspects, and limiting the number of children treated inappropriately."

Dr Suzanne Anderson from Brighton and Sussex Medical School, who led recruitment in Malawi, said: "This study has highlighted the benefit of research institutions in Europe collaborating with hospitals in Africa to apply sophisticated technology to major public health problems."

Professor Robert Heyderman, Director of the Malawi-Liverpool-Wellcome Trust Clinical Research Programme based in Blantyre at the University of Malawi College of Medicine, where part of this study took place, said: "Childhood TB has been neglected by both researchers and policy makers for too long. A test that potentially allows TB to be distinguished from other childhood diseases in Africa such as pneumonia, severe bacterial infection and HIV is a critically important tool for both clinicians and for the testing of new drugs and vaccines."